United Therapeutics EVP Paul A. Mahon Sells 5,000 Shares (UTHR)
United Therapeutics (NASDAQ:UTHR) EVP Paul A. Mahon sold 5,000 shares of the stock on the open market in a transaction dated Thursday, August 28th. The stock was sold at an average price of $92.07, for a total value of $460,350.00. Following the sale, the executive vice president now directly owns 34,832 shares in the company, valued at approximately $3,206,982. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link.
United Therapeutics (NASDAQ:UTHR) traded up 28.51% on Friday, hitting $117.83. The stock had a trading volume of 6,443,280 shares. United Therapeutics has a 1-year low of $70.95 and a 1-year high of $118.76. The stock’s 50-day moving average is $92.3 and its 200-day moving average is $95.55. The company has a market cap of $5.570 billion and a price-to-earnings ratio of 17.72.
United Therapeutics (NASDAQ:UTHR) last posted its quarterly earnings results on Tuesday, July 29th. The company reported $2.57 EPS for the quarter, beating the Thomson Reuters consensus estimate of $1.75 by $0.82. The company had revenue of $322.80 million for the quarter, compared to the consensus estimate of $308.04 million. During the same quarter in the prior year, the company posted $1.52 earnings per share. The company’s quarterly revenue was up 15.0% on a year-over-year basis. Analysts expect that United Therapeutics will post $8.55 EPS for the current fiscal year.
A number of research firms have recently commented on UTHR. Analysts at Wedbush raised their price target on shares of United Therapeutics from $133.00 to $141.00 in a research note on Friday. They now have an “outperform” rating on the stock. Separately, analysts at Standpoint Research raised their price target on shares of United Therapeutics from $118.00 to $140.00 in a research note on Friday. They now have a “buy” rating on the stock. Finally, analysts at Zacks upgraded shares of United Therapeutics from a “neutral” rating to an “outperform” rating in a research note on Thursday, August 21st. They now have a $112.00 price target on the stock. Five equities research analysts have rated the stock with a hold rating and seven have assigned a buy rating to the company’s stock. The stock presently has a consensus rating of “Buy” and a consensus target price of $104.87.
United Therapeutics Corporation is a biotechnology company focused on the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening conditions.
Receive News & Ratings for United Therapeutics Co Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for United Therapeutics Co and related companies with Analyst Ratings Network's FREE daily email newsletter.